Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Zymeworks
gptkb:Protalix_Biotherapeutics |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:CEO |
Jean-Jacques_Bienaimé
|
| gptkbp:clinicalTrials |
ongoing
published in peer-reviewed journals Phase 1 studies Phase 2 studies Phase 3 studies expanded access programs focus on pediatric populations patient recruitment efforts |
| gptkbp:collaborations |
with universities
with research institutions with global health organizations |
| gptkbp:communityEngagement |
patient advocacy initiatives
|
| gptkbp:culturalHeritage |
commitment to workplace diversity
|
| gptkbp:financialPerformance |
strong revenue growth
|
| gptkbp:focus |
biopharmaceuticals
|
| gptkbp:founded |
1997
|
| gptkbp:founder |
gptkb:Daniel_K._Spiegelman
|
| gptkbp:globalPresence |
operates in over 30 countries
|
| gptkbp:hasCapacity |
programs for patients and families
|
| gptkbp:headCoach |
gptkb:Dr._Hank_Fuchs
over 1,500 employees |
| gptkbp:headquarters |
gptkb:San_Rafael,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
BioMarin Pharmaceutical
|
| gptkbp:innovation |
focus on breakthrough therapies
|
| gptkbp:investmentFocus |
publicly traded company
in R&D |
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
approximately $12 billion
|
| gptkbp:marketSegment |
focus on niche markets
|
| gptkbp:partnerships |
biotech companies
various academic institutions |
| gptkbp:philanthropy |
support for rare disease communities
|
| gptkbp:products |
gptkb:Brineura
gptkb:Palynziq gptkb:Vimizim Kuvan Naglazyme |
| gptkbp:regulatoryCompliance |
adherence to global standards
FDA_approved_products EMA_approved_products |
| gptkbp:research |
grants for rare disease research
|
| gptkbp:research_areas |
metabolic disorders
oncology neurological disorders musculoskeletal disorders hematological disorders |
| gptkbp:researchFocus |
gene therapy
enzyme replacement therapy small molecule drugs |
| gptkbp:revenue |
approximately $1 billion annually
|
| gptkbp:specializesIn |
rare diseases
|
| gptkbp:stockSymbol |
BMRN
|
| gptkbp:strategicGoals |
improve patient outcomes
increase market share expand product portfolio enhance global reach |
| gptkbp:sustainability |
environmental responsibility initiatives
|
| gptkbp:tributaryOf |
multiple investigational therapies
|